BRAF and melanoma: To evaluate whether induction of TRIM16 expression was necessary for vemurafenib effects on melanoma cell viability we silenced TRIM16 gene expression using two TRIM16-specific siRNA's and treated BRAF-mutant A375 melanoma cells with vemurafenib.